Is there a role for sulphasalazine in axial  spondyloarthritis in the era of TNF inhibition?
Our findings support current recommendations of SSZ as an optional treatment in SpA patients with peripheral disease, although overall responses were modest. Initial treatment with SSZ does not seem to impair later TNFi response.
The indigenous hydroxyapa tite implant is a good biomaterial for socket reconstruction.